NYSEMKT: OSTX
Os Therapies Inc Earnings Dates, Reports, Calls

Os Therapies earnings were -$10.9M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest OSTX earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$5.0M, up 72.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, OSTX reported annual earnings of -$10.9M, with 37.5% growth.

OSTX earnings history

Current Revenue
$0.0
Current Earnings
-$10.9M
Current Profit Margin
0%

OSTX Return on Equity

Insufficient data to display

OSTX undefined

Current Company
-439.5%
Current Industry
-0.4%
OSTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when OSTX announces earnings.

OSTX undefined

Current Company
-749.45%
Current Industry
5.9%
OSTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

OSTX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
OSTX-$6.83M-$10.89MN/A-$0.88
XFOR-$25.99M-$37.45MN/A-$0.19
NRXP-$24.89M-$25.13MN/A-$2.36
SRZN-$60.60M-$63.56MN/A-$21.67
KLRS-$58.62M-$58.77MN/A-$11.73

Os Therapies Earnings Reports & History FAQ

What were Os Therapies's earnings last quarter?

Os Therapies (NYSEMKT: OSTX) reported Q4 2024 earnings per share (EPS) of -$0.24, up 71.76% year over year. Total OSTX earnings for the quarter were -$4.96 million. In the same quarter last year, Os Therapies's earnings per share (EPS) was -$0.85.

If you're new to stock investing, here's how to buy Os Therapies stock.

Is Os Therapies profitable or losing money?

As of the last Os Therapies earnings report, Os Therapies is currently losing money. Os Therapies's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$8.88 million, a 14.01% increase year over year.

What was OSTX's earnings growth in the past year?

As of Os Therapies's earnings date in Q2 2025, Os Therapies's earnings has grown year over year. OSTX earnings in the past year totalled -$10.89 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.